Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI; Alberta Provincial Pediatric Enteric Infection Team (APPETITE), Nettel-Aguirre A, Chuck A, Lee B, Johnson D, Currie G, Talbot J, Jiang J, Dickinson J, Kellner J, MacDonald J, Svenson L, Chui L, Louie M, Lavoie M, Eltorki M, Vanderkooi O, Tellier R, Ali S, Drews S, Graham T, Pang XL.

Clin Infect Dis. 2016 May 15;62(10):1251-1258. doi: 10.1093/cid/ciw099. Epub 2016 Feb 24.

2.

Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009-2012.

Launders N, Byrne L, Jenkins C, Harker K, Charlett A, Adak GK.

BMJ Open. 2016 Jan 29;6(1):e009933. doi: 10.1136/bmjopen-2015-009933.

3.

Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides.

Fernandez-Brando RJ, Yamaguchi N, Tahoun A, McAteer SP, Gillespie T, Wang D, Argyle SA, Palermo MS, Gally DL.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):459-70. doi: 10.1128/AAC.02085-15.

4.

Genomic characterisation of an endometrial pathogenic Escherichia coli strain reveals the acquisition of genetic elements associated with extra-intestinal pathogenicity.

Goldstone RJ, Popat R, Schuberth HJ, Sandra O, Sheldon IM, Smith DG.

BMC Genomics. 2014 Dec 6;15:1075. doi: 10.1186/1471-2164-15-1075.

5.

Neuropsychological outcome after complicated Shiga toxin-producing Escherichia coli infection.

Simova O, Weineck G, Schuetze T, Wegscheider K, Panzer U, Stahl RA, Gerloff C, Magnus T.

PLoS One. 2014 Jul 22;9(7):e103029. doi: 10.1371/journal.pone.0103029. eCollection 2014.

7.

Underlying mechanism of antimicrobial activity of chitosan microparticles and implications for the treatment of infectious diseases.

Jeon SJ, Oh M, Yeo WS, Galvão KN, Jeong KC.

PLoS One. 2014 Mar 21;9(3):e92723. doi: 10.1371/journal.pone.0092723. eCollection 2014.

8.

Chronic sequelae of E. coli O157: systematic review and meta-analysis of the proportion of E. coli O157 cases that develop chronic sequelae.

Keithlin J, Sargeant J, Thomas MK, Fazil A.

Foodborne Pathog Dis. 2014 Feb;11(2):79-95. doi: 10.1089/fpd.2013.1572. Epub 2013 Nov 27. Review.

9.

Characteristics of clinical Shiga toxin-producing Escherichia coli isolated from British Columbia.

Allen KJ, Laing CR, Cancarevic A, Zhang Y, Mesak LR, Xu H, Paccagnella A, Gannon VP, Hoang L.

Biomed Res Int. 2013;2013:878956. doi: 10.1155/2013/878956. Epub 2013 Oct 2.

10.

Marked synergistic bactericidal effects and mode of action of medium-chain fatty acids in combination with organic acids against Escherichia coli O157:H7.

Kim SA, Rhee MS.

Appl Environ Microbiol. 2013 Nov;79(21):6552-60. doi: 10.1128/AEM.02164-13. Epub 2013 Aug 16.

11.

Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.

Pinto A, Jacobsen M, Geoghegan PA, Cangelosi A, Cejudo ML, Tironi-Farinati C, Goldstein J.

PLoS One. 2013 Jul 23;8(7):e70020. doi: 10.1371/journal.pone.0070020. Print 2013.

12.

Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection.

Zoufaly A, Cramer JP, Vettorazzi E, Sayk F, Bremer JP, Koop I, de Weerth A, Schmiedel S, Jordan S, Fraedrich K, Asselborn NH, Nitschke M, Neumann-Grutzeck C, Magnus T, Rüther C, Fellermann K, Stahl RK, Wegscheider K, Lohse AW.

PLoS One. 2013;8(3):e59209. doi: 10.1371/journal.pone.0059209. Epub 2013 Mar 22. Erratum in: PLoS One. 2014;9(3):e91617.

13.

Regional immune response to immunization with Escherichia coli O157:H7-derived intimin in cattle.

Boland KG, Hayles AN, Miller CB, Kerr T, Brown WC, Lahmers KK.

Clin Vaccine Immunol. 2013 Apr;20(4):562-71. doi: 10.1128/CVI.00743-12. Epub 2013 Feb 13.

14.

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli.

Hauswaldt S, Nitschke M, Sayk F, Solbach W, Knobloch JK.

Curr Infect Dis Rep. 2013 Feb;15(1):4-9. doi: 10.1007/s11908-012-0302-4.

15.

Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Keir LS, Marks SD, Kim JJ.

Drug Des Devel Ther. 2012;6:195-208. doi: 10.2147/DDDT.S25757. Epub 2012 Jul 19. Review.

16.

Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak.

Corogeanu D, Willmes R, Wolke M, Plum G, Utermöhlen O, Krönke M.

BMC Microbiol. 2012 Aug 1;12:160. doi: 10.1186/1471-2180-12-160.

17.

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study.

Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T; EHEC-HUS consortium.

BMJ. 2012 Jul 19;345:e4565. doi: 10.1136/bmj.e4565.

18.

Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.

Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI.

Clin Infect Dis. 2012 Jul;55(1):33-41. doi: 10.1093/cid/cis299. Epub 2012 Mar 19.

19.

Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.

Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H.

Antimicrob Agents Chemother. 2012 Jun;56(6):3277-82. doi: 10.1128/AAC.06315-11. Epub 2012 Mar 5.

20.

Impact of the nature and size of the polymeric backbone on the ability of heterobifunctional ligands to mediate shiga toxin and serum amyloid p component ternary complex formation.

Kitov PI, Paszkiewicz E, Sadowska JM, Deng Z, Ahmed M, Narain R, Griener TP, Mulvey GL, Armstrong GD, Bundle DR.

Toxins (Basel). 2011 Sep;3(9):1065-88. doi: 10.3390/toxins3091065. Epub 2011 Aug 25.

Supplemental Content

Support Center